Expression of androgen receptor and its regulatory molecule Lin28 in non‑luminal subtype breast cancer
| Autor: | Kwanlada Mitpakdi, Tuenjai Chuangsuwanich, Norasate Samarnthai, Anchalee Kulprom, Wanee Pongthong, Pornchai O‑Charoenrat, Doonyapat Sa‑Nguanraksa, Thawornchai Limjindaporn |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Lin28
Cancer Research non-luminal subtypes 03 medical and health sciences breast cancer 0302 clinical medicine Breast cancer androgen receptor medicine Clinical significance skin and connective tissue diseases Tissue microarray Oncogene business.industry human epidermal growth factor receptor 2 Cancer Articles medicine.disease Molecular medicine Androgen receptor Oncology 030220 oncology & carcinogenesis Cancer research Immunohistochemistry 030211 gastroenterology & hepatology business |
| Zdroj: | Molecular and Clinical Oncology |
| ISSN: | 2049-9469 2049-9450 |
| DOI: | 10.3892/mco.2020.2029 |
| Popis: | Androgen receptor (AR) was associated with favourable outcome in luminal breast cancer. However, the role of AR in non-luminal breast cancer remains inconclusive. The aim of the present study was to evaluate the clinical significance of the AR and its regulatory pathway in non-luminal subtypes of breast cancer. In total, 284 breast cancer patients were recruited from January 2007 to January 2016. Tissue microarrays were constructed from archival paraffin blocks and assessed for AR and its regulatory molecule, Lin28, by immunohistochemistry. The association between AR and Lin28 expression and clinicopathological parameters was analyzed. Results showed that AR and Lin28 were co-expressed. No association between these proteins and clinicopathological parameters, and survival outcome was found. However, a higher proportion of the patients with AR and Lin28 expression were observed in HER2 subtype. In conclusion, Lin28 may be a novel marker for prognosis and targeted for treatment in HER2 subtype breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|